Payment overview · 2025
General Payments
$1,701.85
69 reported records · 23 companies
Healthcare provider profile · identity verified
Merwin F Richard, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · JERSEY CITY, NJ · NPI 1043233513
Verified facts
What the public records show
CMS Open Payments records show Merwin F Richard, M.D received $1,701.85 in general payments during 2025 across 69 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $466.96 | 27.4% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $231.84 | 13.6% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $165.89 | 9.8% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $154.29 | 9.1% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$103.19 | 6.1% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $86.25 | 5.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.75 | 4.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.54 | 4.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.11 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.10 | 2.1% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $33.84 | 2.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.27 | 1.9% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $24.40 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.24 | 1.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $22.92 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.50 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.98 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.01 | 1.1% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $17.71 | 1.0% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $15.52 | 0.9% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $15.50 | 0.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.04 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.00 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,701.85 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $466.96 | 15 | 2025 |
Source payment records
|
|||||
| ABSOLUTE PRO Normalized: absolute pro |
Device | Abbott Laboratories | $165.89 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $154.29 | 9 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $103.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $77.42 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $54.53 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $54.53 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.61 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.12 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $33.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $33.84 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 62 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 39 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 323 | 151 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 251 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 97 |
| Metformin Hcl | Metformin Hcl | 200 | 86 |
| Ibuprofen | Ibuprofen | 199 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 83 |
| Alprazolam | Alprazolam | 159 | 44 |
| Omeprazole | Omeprazole | 154 | 72 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 147 | 70 |
| Gabapentin | Gabapentin | 140 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 36 |
| Furosemide | Furosemide | 129 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 126 | 58 |
| Jardiance | Empagliflozin | 107 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 30 |
| Losartan Potassium | Losartan Potassium | 94 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 42 |
| Eliquis | Apixaban | 86 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 21 |
| Carvedilol | Carvedilol | 78 | 31 |
| Simvastatin | Simvastatin | 78 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 23 |
| Rybelsus | Semaglutide | 62 | 11 |
| Montelukast Sodium | Montelukast Sodium | 60 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 29 |
| Farxiga | Dapagliflozin Propanediol | 54 | 22 |
| Meclizine Hcl | Meclizine Hcl | 51 | 31 |
| Ozempic | Semaglutide | 51 | 16 |
| Famotidine | Famotidine | 48 | 23 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 46 | 15 |
| Tramadol Hcl | Tramadol Hcl | 46 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | 17 |
| Linzess | Linaclotide | 44 | 12 |
| Entresto | Sacubitril/Valsartan | 43 | 13 |
| Glimepiride | Glimepiride | 41 | 16 |
| Lisinopril | Lisinopril | 41 | 28 |
| Allopurinol | Allopurinol | 37 | 19 |
| Tradjenta | Linagliptin | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 23 |
| Meloxicam | Meloxicam | 33 | 14 |
| Naproxen | Naproxen | 33 | 26 |
| Vascepa | Icosapent Ethyl | 33 | 17 |
| Alendronate Sodium | Alendronate Sodium | 32 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 15 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Valsartan | Valsartan | 30 | 14 |
| Januvia | Sitagliptin Phosphate | 29 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | 11 |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | 11 |
| Memantine Hcl | Memantine Hcl | 26 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | 18 |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ibu | Ibuprofen | 21 | 14 |
| Atenolol | Atenolol | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | 11 |
| Lidocaine | Lidocaine | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Fenofibrate | Fenofibrate | 18 | 11 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Finasteride | Finasteride | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Plavix | Clopidogrel Bisulfate | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,701.85 · 69 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ABSOLUTE PRO, AIRSUPRA, AMS 700, AREXVY, BREZTRI, CAPVAXIVE, COBALT DR MRI SURESCAN, Dexcom G6 Transmitter, Exablate, FARXIGA, FFRct, INSPIRE, JARDIANCE, Kerecis GraftGuide, Kerecis SurgiClose, Kerendia, LEQVIO, LifeVest, Ozempic, Paradise Ultrasound Renal Denervation System, REPATHA, Rybelsus, SHINGRIX, Saxenda, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, VYNDAQEL, Wegovy, Xhance, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error